[go: up one dir, main page]

AR051928A1 - Peptidos y derivados tipo apl de la hsp60 y composiciones farmaceuticas - Google Patents

Peptidos y derivados tipo apl de la hsp60 y composiciones farmaceuticas

Info

Publication number
AR051928A1
AR051928A1 ARP050103950A ARP050103950A AR051928A1 AR 051928 A1 AR051928 A1 AR 051928A1 AR P050103950 A ARP050103950 A AR P050103950A AR P050103950 A ARP050103950 A AR P050103950A AR 051928 A1 AR051928 A1 AR 051928A1
Authority
AR
Argentina
Prior art keywords
peptides
pharmaceutical compositions
hsp60
derivatives
rheumatoid arthritis
Prior art date
Application number
ARP050103950A
Other languages
English (en)
Inventor
Horta Maria Del Carm Dominguez
Palomares Gabriel Ramon Padron
Marin Nelia Lopez
Perez Norailys Lorenzo
Betancourt Ariana Barbera
Garcia Ariadna Hernandez
Cordova Vivian Morera
Diaz Carelia Cosme
Garcia Nelson J Merino
Bonachea Ariel Vazquez
Alba Jose Suarez
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of AR051928A1 publication Critical patent/AR051928A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Péptidos de la proteína humana de estrés térmico de 60 kDa que constituyen epitopes para células T, así como péptidos derivados de ellos, los cuales están modificados en los sitios de contacto con la molécula MHC, utiles para inducir mecanismos de tolerancia periférica, en particular mecanismos inductores de anergia o mediados por clones de célula T regulatorias en pacientes con Artritis Reumatoide. La presente también refiere composiciones farmacéuticas que comprenden tales péptidos para tratamiento de la Artritis Reumatoide.
ARP050103950A 2004-09-24 2005-09-21 Peptidos y derivados tipo apl de la hsp60 y composiciones farmaceuticas AR051928A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20040207A CU23504A1 (es) 2004-09-24 2004-09-24 Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas

Publications (1)

Publication Number Publication Date
AR051928A1 true AR051928A1 (es) 2007-02-21

Family

ID=40273413

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP050103950A AR051928A1 (es) 2004-09-24 2005-09-21 Peptidos y derivados tipo apl de la hsp60 y composiciones farmaceuticas
ARP090105137A AR074924A2 (es) 2004-09-24 2009-12-28 Peptidos y derivados tipo peptido ligando alterado (apl) de la hsp60 y composiciones farmaceuticas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP090105137A AR074924A2 (es) 2004-09-24 2009-12-28 Peptidos y derivados tipo peptido ligando alterado (apl) de la hsp60 y composiciones farmaceuticas

Country Status (17)

Country Link
US (2) US8383771B2 (es)
EP (2) EP2371847B1 (es)
JP (1) JP4755649B2 (es)
KR (2) KR101035283B1 (es)
CN (2) CN101935345B (es)
AR (2) AR051928A1 (es)
AT (1) ATE546462T1 (es)
AU (2) AU2005287757B2 (es)
BR (2) BR122018077204B8 (es)
CA (2) CA2797769C (es)
CU (1) CU23504A1 (es)
DK (2) DK1803732T3 (es)
ES (2) ES2445707T3 (es)
MX (1) MX2007003624A (es)
RU (1) RU2361877C2 (es)
WO (1) WO2006032216A2 (es)
ZA (1) ZA200702938B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2423221B1 (en) 2007-01-30 2015-04-29 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
CU23701A1 (es) * 2008-12-29 2011-09-21 Ct Ingenieria Genetica Biotech Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i
EP3366308A1 (en) * 2009-09-06 2018-08-29 Protab Ltd. Humanized antibodies specific for hsp65-derived peptide-6 methods and uses thereof
WO2011059758A2 (en) * 2009-10-28 2011-05-19 Argentis Pharmaceuticals, Llc Apls for treating arthritis
CU24508B1 (es) * 2017-12-29 2021-04-07 Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma Composición farmacéutica que comprende péptido tipo apl
CU20200026A7 (es) * 2020-04-13 2021-11-04 Ct Ingenieria Genetica Biotecnologia Péptido para el tratamiento del síndrome de la tormenta de citocinas
CN111870697B (zh) * 2020-09-18 2022-09-09 山东鲁抗医药股份有限公司 糖类物质在提高apl型衍生肽稳定性中的应用和冻干组合物
KR102333645B1 (ko) 2021-07-27 2021-12-02 (주)문화전기 각도조절이 용이한 엘이디조명시스템
CN117883547A (zh) * 2021-07-30 2024-04-16 河北菲尼斯生物技术有限公司 Se-dr亲和肽在制备治疗风湿疾病的药物中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8701163A (nl) 1986-09-09 1988-04-05 Nederlanden Staat Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits.
NL8703107A (nl) 1987-12-22 1989-07-17 Nederlanden Staat Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten.
US5773570A (en) 1994-05-20 1998-06-30 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
GB9419553D0 (en) 1994-09-27 1994-11-16 Univ Bristol Polypeptides and their use in the treatment of auto-immune disease
US6180103B1 (en) 1994-12-21 2001-01-30 Yeda Research And Development Co., Ltd. Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes
GB9519737D0 (en) 1995-09-27 1995-11-29 Peptide Therapeutics Ltd Polypeptides and their use in treatment and prophylaxis of auto-immune
TW575583B (en) * 1996-04-24 2004-02-11 Akzo Nobel Nv Novel peptides suitable for use in antigen specific immunosuppressive therapy
US5993803A (en) 1996-08-30 1999-11-30 Yeda Research And Development Co., Ltd. Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
GB9911772D0 (en) 1999-05-21 1999-07-21 Semmelweis University Of Medic Diagnosis and treatment of atherosclerosis
US20020169302A1 (en) * 1999-08-23 2002-11-14 Genesis Research And Development Corp. Ltd. Compositions isolated from bovine mammary gland and methods for their use
NZ519348A (en) * 1999-12-15 2006-04-28 Develogen Israel Ltd Fragments and antagonists of heat shock protein 60
US7534419B2 (en) 2001-01-19 2009-05-19 Depuy Mitek, Inc. Methods of diagnosis and treatment of osteoporosis

Also Published As

Publication number Publication date
CN101065398A (zh) 2007-10-31
BRPI0515893A (pt) 2008-08-12
AU2005287757A1 (en) 2006-03-30
BR122018077204B8 (pt) 2021-07-27
EP2371847A1 (en) 2011-10-05
MX2007003624A (es) 2007-06-13
JP2008514553A (ja) 2008-05-08
CN101935345B (zh) 2013-12-11
CA2581110C (en) 2013-04-02
JP4755649B2 (ja) 2011-08-24
BRPI0515893B8 (pt) 2021-05-25
AU2005287757B2 (en) 2010-07-29
RU2361877C2 (ru) 2009-07-20
CN101935345A (zh) 2011-01-05
BR122018077204B1 (pt) 2020-01-28
DK2371847T3 (da) 2014-02-03
CU23504A1 (es) 2010-04-13
US20090171069A1 (en) 2009-07-02
US20100144642A1 (en) 2010-06-10
KR20070073787A (ko) 2007-07-10
ATE546462T1 (de) 2012-03-15
DK1803732T3 (da) 2012-05-29
KR20100028645A (ko) 2010-03-12
EP1803732B1 (en) 2012-02-22
AR074924A2 (es) 2011-02-23
BRPI0515893A8 (pt) 2019-01-02
ZA200702938B (en) 2008-08-27
EP2371847B1 (en) 2013-11-20
BRPI0515893B1 (pt) 2020-09-15
KR101054332B1 (ko) 2011-08-04
EP1803732A2 (en) 2007-07-04
CA2797769A1 (en) 2006-03-30
US8324164B2 (en) 2012-12-04
RU2007115411A (ru) 2008-10-27
CN101065398B (zh) 2012-12-19
AU2010219312A1 (en) 2010-09-23
WO2006032216A2 (es) 2006-03-30
WO2006032216A3 (es) 2007-05-18
US8383771B2 (en) 2013-02-26
ES2386498T3 (es) 2012-08-22
ES2445707T3 (es) 2014-03-04
CA2797769C (en) 2015-09-15
AU2010219312B2 (en) 2011-10-06
KR101035283B1 (ko) 2011-05-18
CA2581110A1 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
ECSP099379A (es) Anticuerpos anti-factor d humanizados
EA201270713A1 (ru) Белки на основе фибронектина с каркасными доменами, которые связывают ил-23
BR112021005769A2 (pt) proteínas de ligação a dll3 e métodos de uso
PE20081501A1 (es) Polipeptidos heterologos il-17a/f y usos terapeuticos de los mismos
MX2018013087A (es) Anticuerpos anti-factor d humanizados y sus usos.
MX2019006727A (es) Nuevos receptores de celulas t y terapia inmunologica que los utiliza.
AR067666A1 (es) Proteinas de union al antigeno del receptor de il-18
PE20200152A1 (es) Receptores de union a antigeno mejorados
GT201000148A (es) Anticuerpos antimesotelina y usos de los mismos
CY1119739T1 (el) Καινοτομος ανοσοθεραπεια εναντι ογκων του εγκεφαλου
CY1117115T1 (el) Καινοτομος ανοσοθεραπεια εναντι ογκων και νευρωνων του εγκεφαλου
AR074924A2 (es) Peptidos y derivados tipo peptido ligando alterado (apl) de la hsp60 y composiciones farmaceuticas
EA201892619A1 (ru) Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CO7121348A2 (es) Proteínas de fusión de interleuquina-2 y usos de las mismas
BR112013031262A2 (pt) "exotoxinas a de pseudomonas com menos epítopos imunogênicos de célula b e t, e seu uso no tratamento e prevenção de câncer, bem como molécula quimérica, ácido nucleico, vetor de expressão, células, composição farmacêutica e métodos para inibir crescimento de célula-alvo e de produção de endotoxinas a de pseudomonas e de molécula quimérica".
EA201591766A1 (ru) Мутеины интерлейкина-2 для экспансии регуляторных т-клеток
MX395287B (es) Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos.
AR071874A1 (es) Proteinas de dominio de armazon basadas en fibronectina multivalentes
BR112018072946A2 (pt) proteínas de fusão a gdf15 e usos das mesmas
BR112012009854B8 (pt) proteína de ligação de antígeno isolada recombinante que liga il-23, composição farmacêutica, molécula de ácido nucleico isolada recombinante, vetor recombinante, método de confecção da referida proteína de ligação e uso da mesma
BR112015021819A2 (pt) Tratamento de câncer utilizando receptor quimérico de antígeno humanizado anti-cd19
NI201200134A (es) Polipéptidos agonistas que se enlazan a dr5
CL2009001277A1 (es) Anticuerpo que enlaza especificamente el flt3 humano; fragmento de cualquiera de los anticuerpos antes dichos; acido polinucleico aislado; vector de expresion; celula recombinante; composicion farmaceutica y sus usos; producto que contiene el anticuerpo para tratar cancer
EA201300896A1 (ru) Мутантные полипептиды интерлейкина-2
CR20150016A (es) Anticuerpo monoclonal

Legal Events

Date Code Title Description
FG Grant, registration